This economic evaluation assessed the budget impact of gene therapy for autosomal recessive dystrophic epidermolysis bullosa (RDEB).
The abstract provides insufficient detail to assess study methodology, assumptions, time horizon, or specific cost outcomes.
Explore related topics
